Javier Martínez-Picado

Javier Martínez-Picado

Institut de Recerca de la Sida - IrsiCaixa

Life & Medical Sciences

Javier Martínez-Picado is ICREA Research Professor at the irsiCaixa AIDS Research Institute in Barcelona, an institution that works to advance clinical research and translate results into patients care. He is also associate professor at the Univ of Vic. He received his PhD from the Univ of Barcelona where he subsequently became associate professor lecturing on different microbiology-related subjects. In 1996, he joined the Massachusetts General Hospital as postdoctoral fellow of the Harvard Medical School, where he engaged in AIDS research. In 2000, he obtained a position as biomedical researcher of the Spanish Health Department appointed to the Hosp Germans Trias in Badalona. In 2006 he obtained his current ICREA position. Dr. Martínez-Picado serves on different government, academic and industry advisory boards and has published extensively on virology and immunology subjects, mainly related to HIV pathogenesis, in international journals.

Research interests

The research of our group focuses on characterizing the immune-virological mechanisms of viral pathogenesis in human diseases, including HIV-1, Ebola virus, Arenaviruses, and more recently SARS-CoV-2. Our program has a translational character with the goal of investigating potential new viral therapeutic strategies, especially in the HIV/AIDS field, through both basic and applied research. We closely collaborate with other research groups within irsiCaixa, as well as with national and international biomedical institutes. Our programme focuses on three priority areas in the HIV research: 1) HIV cure, 2) Viral pathogenesis mediated by dendritic cells, 3) Extreme HIV infection phenotypes. During 2020, an additional research line in SARS-CoV2 has been incorporated to the team.

Selected publications

- Bastard P et al 2020, 'Autoantibodies against type I IFNs in patients with life-threatening COVID-19', Science, 370, 6515, 423 - +.

- Abdel-Mohsen M et al 2020, 'Recommendations for measuring HIV reservoir size in cure-directed clinical trials', Nat Med 26(9):1339-50

- Gonzalez-Cao M et al, 2020, 'Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection', JAMA Oncol 6(7):1063-7

- Eberhard J et al 2020, 'Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1', Sci Transl Med 12, 542

- Gupta RK et al. 2020, 'Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report', Lancet HIV 7(5):E340-7.

- Puertas MC et al 2020, 'Pan-resistant HIV-1 emergence in the INSTI era: a case study'. Lancet Microbe 1(3):e130-5.

- Adland E et al 2020, 'Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection'. Nat Commun 11(1):1767

- Moron-Lopez S et al 2020, 'The genome-wide methylation profile of CD4+ T cells from HIV-infected individuals identifies distinct patterns associated with disease progression', Clin Infect Dis ciaa1047

- Gálvez C et al. 2020. 'Extremely Low Viral Reservoir in Treated Chronically HIV-1-infected individuals'. EBioMedicine 57:102830

- Bayón A et al 2020, 'HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design'. J Antimicrob Chemother 75(8):2258-63

- Casado C et al 2020, 'Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure'. Sci Rep 10:1902

- Perez-Zsolt D et al 2020, 'When dendritic cells go viral: the role of Siglec-1 in host defense and dissemination of enveloped viruses', Viruses 12(8)